PDT Partners LLC Sells 6,266 Shares of Cencora, Inc. (NYSE:COR)

PDT Partners LLC reduced its stake in Cencora, Inc. (NYSE:COR - Free Report) by 37.5% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 10,434 shares of the company's stock after selling 6,266 shares during the quarter. PDT Partners LLC's holdings in Cencora were worth $2,344,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC increased its holdings in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after acquiring an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Cencora in the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC raised its position in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the period. Kentucky Trust Co purchased a new stake in shares of Cencora during the 4th quarter valued at approximately $33,000. Finally, WASHINGTON TRUST Co boosted its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after buying an additional 46 shares during the period. Institutional investors own 97.52% of the company's stock.

Cencora Price Performance

Cencora stock traded up $1.74 during mid-day trading on Friday, hitting $292.17. 1,046,574 shares of the company traded hands, compared to its average volume of 1,508,616. The stock has a fifty day moving average price of $272.65 and a 200-day moving average price of $251.53. The stock has a market cap of $56.66 billion, a price-to-earnings ratio of 41.56, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. Cencora's payout ratio is 31.29%.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. The trade was a 8.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock valued at $13,580,967 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have issued reports on COR. Wells Fargo & Company increased their target price on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Morgan Stanley set a $288.00 price objective on Cencora in a report on Tuesday, April 15th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Finally, Bank of America boosted their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $290.00.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.